<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34103575</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>FGF23, a novel muscle biomarker detected in the early stages of ALS.</ArticleTitle><Pagination><StartPage>12062</StartPage><MedlinePgn>12062</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-91496-6</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive muscle weakness. Skeletal muscle is a prime source for biomarker discovery since it is one of the earliest sites to manifest disease pathology. From a prior RNA sequencing project, we identified FGF23 as a potential muscle biomarker in ALS. Here, we validate this finding with a large collection of ALS muscle samples and found a 13-fold increase over normal controls. FGF23 was also increased in the SOD1<sup>G93A</sup> mouse, beginning at a very early stage and well before the onset of clinical symptoms. FGF23 levels progressively increased through end-stage in the mouse. Immunohistochemistry of ALS muscle showed prominent FGF23 immunoreactivity in the endomysial connective tissue and along the muscle membrane and was significantly higher around grouped atrophic fibers compared to non-atrophic fibers. ELISA of plasma samples from the SOD1<sup>G93A</sup> mouse showed an increase in FGF23 at end-stage whereas no increase was detected in a large cohort of ALS patients. In conclusion, FGF23 is a novel muscle biomarker in ALS and joins a molecular signature that emerges in very early preclinical stages. The early appearance of FGF23 and its progressive increase with disease progression offers a new direction for exploring the molecular basis and response to the underlying pathology of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Si</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kazamel</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Thaddaeus</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kentrup</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine (Division of Nephrology and Hypertension), University of Alabama at Birmingham, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faul</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine (Division of Nephrology and Hypertension), University of Alabama at Birmingham, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alesce</LastName><ForeName>Lyndsy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Civitan 545C, 1530 3rd Avenue South, Birmingham, AL, 35294, USA. phking@uabmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. phking@uabmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA. phking@uabmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS111275</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092651</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX004419</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK125459</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL145528</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717427">FGF23 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717428">Fgf23 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>7Q7P4S7RRE</RegistryNumber><NameOfSubstance UI="D000089703">Fibroblast Growth Factor-23</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089703" MajorTopicYN="N">Fibroblast Growth Factor-23</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34103575</ArticleId><ArticleId IdType="pmc">PMC8187665</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-91496-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-91496-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benatar M, et al. ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve. 2016;53:169&#x2013;182. doi: 10.1002/mus.24979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24979</ArticleId><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: Opportunities and limitations. Nat. Rev. Neurol. 2011;7:631&#x2013;638. doi: 10.1038/nrneurol.2011.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.151</ArticleId><ArticleId IdType="pubmed">21989244</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69. doi: 10.1212/wnl.0000000000009559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, et al. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2013;1143. doi: 10.1212/wnl.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Loeffler JP. Neuromuscular junction destruction during amyotrophic lateral sclerosis: Insights from transgenic models. Curr. Opin. Pharmacol. 2009;9:341&#x2013;346. doi: 10.1016/j.coph.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2009.03.007</ArticleId><ArticleId IdType="pubmed">19386549</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney EB, de Winter F, Verhaagen J. ALS as a distal axonopathy: Molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, et al. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan T, et al. Wnt antagonist FRZB is a muscle biomarker of denervation atrophy in amyotrophic lateral sclerosis. Sci. Rep. 2020;10:16679. doi: 10.1038/s41598-020-73845-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73845-z</ArticleId><ArticleId IdType="pmc">PMC7541525</ArticleId><ArticleId IdType="pubmed">33028902</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis. Neurobiol. Dis. 2018;114:85&#x2013;94. doi: 10.1016/j.nbd.2018.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.02.009</ArticleId><ArticleId IdType="pmc">PMC5891369</ArticleId><ArticleId IdType="pubmed">29486297</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. Smads as muscle biomarkers in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2014;1:778&#x2013;787. doi: 10.1002/acn3.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.117</ArticleId><ArticleId IdType="pmc">PMC4241805</ArticleId><ArticleId IdType="pubmed">25493269</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. The vitamin D activator CYP27B1 is upregulated in muscle fibers in denervating disease and can track progression in amyotrophic lateral sclerosis. J. Steroid Biochem. Mol. Biol. 2020;200:105650. doi: 10.1016/j.jsbmb.2020.105650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2020.105650</ArticleId><ArticleId IdType="pmc">PMC7274892</ArticleId><ArticleId IdType="pubmed">32142934</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, et al. Transforming growth factor beta (TGF-beta) is a muscle biomarker of disease progression in ALS and correlates with smad expression. PLoS ONE. 2015;10:e0138425. doi: 10.1371/journal.pone.0138425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138425</ArticleId><ArticleId IdType="pmc">PMC4574401</ArticleId><ArticleId IdType="pubmed">26375954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazamel M, et al. Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population. Amyotroph. Lateral Scler Frontotemporal Degener. 2013;14:334&#x2013;337. doi: 10.3109/21678421.2013.770030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.770030</ArticleId><ArticleId IdType="pmc">PMC3732496</ArticleId><ArticleId IdType="pubmed">23458155</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol. 2015;69:5&#x2013;67. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Courbebaisse M, Lanske B. Biology of fibroblast growth factor 23: From physiology to pathology. Cold Spring Harb. Perspect. Med. 2018 doi: 10.1101/cshperspect.a031260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a031260</ArticleId><ArticleId IdType="pmc">PMC5932574</ArticleId><ArticleId IdType="pubmed">28778965</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 2003;278:37419&#x2013;37426. doi: 10.1074/jbc.M304544200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M304544200</ArticleId><ArticleId IdType="pubmed">12874285</ArticleId></ArticleIdList></Reference><Reference><Citation>White KE, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000;26:345&#x2013;348. doi: 10.1038/81664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/81664</ArticleId><ArticleId IdType="pubmed">11062477</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc. Natl. Acad. Sci. USA. 2009;106:20960&#x2013;20965. doi: 10.1073/pnas.0911405106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911405106</ArticleId><ArticleId IdType="pmc">PMC2791631</ArticleId><ArticleId IdType="pubmed">19933335</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyke JM, et al. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS) Exp. Neurol. 2016;277:275&#x2013;282. doi: 10.1016/j.expneurol.2016.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.01.008</ArticleId><ArticleId IdType="pmc">PMC4762214</ArticleId><ArticleId IdType="pubmed">26775178</ArticleId></ArticleIdList></Reference><Reference><Citation>David V, Francis C, Babitt JL. Ironing out the cross talk between FGF23 and inflammation. Am. J. Physiol. Renal Physiol. 2017;312:F1&#x2013;F8. doi: 10.1152/ajprenal.00359.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00359.2016</ArticleId><ArticleId IdType="pmc">PMC5283889</ArticleId><ArticleId IdType="pubmed">27582104</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, et al. Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis. Glia. 2020;68:1165&#x2013;1181. doi: 10.1002/glia.23768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23768</ArticleId><ArticleId IdType="pmc">PMC7269115</ArticleId><ArticleId IdType="pubmed">31859421</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3:e123249. doi: 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123249</ArticleId><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol. Rev. 2018;282:121&#x2013;150. doi: 10.1111/imr.12634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12634</ArticleId><ArticleId IdType="pmc">PMC5813811</ArticleId><ArticleId IdType="pubmed">29431212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: Facts beyond expression. Front. Immunol. 2014;5:508&#x2013;508. doi: 10.3389/fimmu.2014.00508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00508</ArticleId><ArticleId IdType="pmc">PMC4204637</ArticleId><ArticleId IdType="pubmed">25374568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo SK, et al. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1. Bone. 2019;129:115055. doi: 10.1016/j.bone.2019.115055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2019.115055</ArticleId><ArticleId IdType="pubmed">31476437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuga K, et al. Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-&#x3b2;1. PLoS ONE. 2020;15:e0231905. doi: 10.1371/journal.pone.0231905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0231905</ArticleId><ArticleId IdType="pmc">PMC7173860</ArticleId><ArticleId IdType="pubmed">32315372</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, et al. PGC-1&#x3b1; silencing compounds the perturbation of mitochondrial function caused by mutant SOD1 in skeletal muscle of ALS mouse model. Front. Aging Neurosci. 2015;7:204. doi: 10.3389/fnagi.2015.00204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00204</ArticleId><ArticleId IdType="pmc">PMC4611176</ArticleId><ArticleId IdType="pubmed">26539112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez D, et al. ALS skeletal muscle shows enhanced TGF-&#x3b2; signaling, fibrosis and induction of fibro/adipogenic progenitor markers. PLoS ONE. 2017;12:e0177649. doi: 10.1371/journal.pone.0177649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177649</ArticleId><ArticleId IdType="pmc">PMC5433732</ArticleId><ArticleId IdType="pubmed">28520806</ArticleId></ArticleIdList></Reference><Reference><Citation>Li DJ, Fu H, Zhao T, Ni M, Shen FM. Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle. Metabolism. 2016;65:747&#x2013;756. doi: 10.1016/j.metabol.2016.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2016.02.009</ArticleId><ArticleId IdType="pubmed">27085781</ArticleId></ArticleIdList></Reference><Reference><Citation>Avin KG, et al. Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am. J. Physiol. Endocrinol. Metab. 2018;315:E594&#x2013;e604. doi: 10.1152/ajpendo.00343.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00343.2017</ArticleId><ArticleId IdType="pmc">PMC6230710</ArticleId><ArticleId IdType="pubmed">29558205</ArticleId></ArticleIdList></Reference><Reference><Citation>Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009;8:235&#x2013;253. doi: 10.1038/nrd2792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2792</ArticleId><ArticleId IdType="pmc">PMC3684054</ArticleId><ArticleId IdType="pubmed">19247306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacchetta J, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J. Bone Miner. Res. 2013;28:46&#x2013;55. doi: 10.1002/jbmr.1740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.1740</ArticleId><ArticleId IdType="pmc">PMC3511915</ArticleId><ArticleId IdType="pubmed">22886720</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985&#x2013;996. doi: 10.1016/j.kint.2016.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.05.019</ArticleId><ArticleId IdType="pmc">PMC5065745</ArticleId><ArticleId IdType="pubmed">27457912</ArticleId></ArticleIdList></Reference><Reference><Citation>Krick S, et al. Fibroblast growth factor 23 and Klotho contribute to airway inflammation. Eur. Respir. J. 2018 doi: 10.1183/13993003.00236-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00236-2018</ArticleId><ArticleId IdType="pmc">PMC6044452</ArticleId><ArticleId IdType="pubmed">29748308</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaya B, Faul C. FGF23 and inflammation-a vicious coalition in CKD. Kidney Int. 2019;96:813&#x2013;815. doi: 10.1016/j.kint.2019.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.05.018</ArticleId><ArticleId IdType="pubmed">31543148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. Mitochondria in amyotrophic lateral sclerosis: A trigger and a target. Neurodegen. Dis. 2004;1:245&#x2013;254. doi: 10.1159/000085063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085063</ArticleId><ArticleId IdType="pubmed">16908975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. Fibroblast growth factor-23 induces cellular senescence in human mesenchymal stem cells from skeletal muscle. Biochem. Biophys. Res. Commun. 2016;470:657&#x2013;662. doi: 10.1016/j.bbrc.2016.01.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.01.086</ArticleId><ArticleId IdType="pubmed">26797283</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi A, et al. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 2007;92:2374&#x2013;2377. doi: 10.1210/jc.2006-2865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2006-2865</ArticleId><ArticleId IdType="pubmed">17374707</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH. Heparan sulfate heterogeneity in skeletal muscle basal lamina: Demonstration by phage display-derived antibodies. J. Neurosci. 2000;20:4099&#x2013;4111. doi: 10.1523/JNEUROSCI.20-11-04099.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-11-04099.2000</ArticleId><ArticleId IdType="pmc">PMC6772625</ArticleId><ArticleId IdType="pubmed">10818145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama M, et al. Heparan sulfate controls skeletal muscle differentiation and motor functions. Biochim. Biophys. Acta. 2020;1864:129707. doi: 10.1016/j.bbagen.2020.129707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2020.129707</ArticleId><ArticleId IdType="pubmed">32810562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, et al. &#x3b1;-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018;553:461&#x2013;466. doi: 10.1038/nature25451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25451</ArticleId><ArticleId IdType="pmc">PMC6007875</ArticleId><ArticleId IdType="pubmed">29342138</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology. 2005;146:4647&#x2013;4656. doi: 10.1210/en.2005-0670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2005-0670</ArticleId><ArticleId IdType="pmc">PMC4140631</ArticleId><ArticleId IdType="pubmed">16081635</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang F, et al. Phosphate homeostasis, inflammation and the regulation of FGF-23. Kidney Blood Press. Res. 2018;43:1742&#x2013;1748. doi: 10.1159/000495393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000495393</ArticleId><ArticleId IdType="pubmed">30504710</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa TS, et al. Sprint and endurance training in relation to redox balance, inflammatory status and biomarkers of aging in master athletes. Nitric Oxide. 2020;102:42&#x2013;51. doi: 10.1016/j.niox.2020.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2020.05.004</ArticleId><ArticleId IdType="pubmed">32565116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso AL, et al. Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases. Ageing Res. Rev. 2018;47:214&#x2013;277. doi: 10.1016/j.arr.2018.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2018.07.004</ArticleId><ArticleId IdType="pubmed">30071357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartali B, Semba RD, Araujo AB. Klotho, FGF21 and FGF23: Novel pathways to musculoskeletal health? J. Frailty Aging. 2013;2:179&#x2013;183. doi: 10.14283/jfa.2013.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jfa.2013.26</ArticleId><ArticleId IdType="pmc">PMC4855080</ArticleId><ArticleId IdType="pubmed">27070923</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath ER, et al. Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study. PLoS ONE. 2019;14:e0213321. doi: 10.1371/journal.pone.0213321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0213321</ArticleId><ArticleId IdType="pmc">PMC6398923</ArticleId><ArticleId IdType="pubmed">30830941</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005;236:1&#x2013;7. doi: 10.1016/j.jns.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>